Heath Canada issued an advisory Friday that some EpiPen and EpiPen Jr auto-injector devices may not easily slide out of their carrier tube — a problem the statement says could delay or prevent emergency treatment, possibly leading to patient disability or death.
Drug shortages have quietly become a chronic problem for Canada’s health-care system. This week alone, more than two dozen new drugs were listed on Canada’s drug shortage website.
Kaléo Pharmaceuticals’ Auvi-Q autoinjector costs more than the EpiPen, but is priced far lower in Canada than in the U.S.
Parents are scrambling to find pharmacies carrying EpiPens for the new school year, as regulators and manufacturers move to address a continuing shortage of the lifesaving devices.
Health Canada says it has approved epinephrine injectors from other companies besides current sole supplier Pfizer, but they have not made a move to start manufacturing in this country.
EpiPen injectors used to treat life-threatening allergic reactions are currently running short, and EpiPen Jr. products may soon do the same, Health Canada says.
U.S. regulator tells maker of the EpiPen injector device that serious component and product failures have been associated with patient deaths and severe illness. CBC | Health News
Mylan finalizes settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen. CBC | Health News
More than seven months after the introduction of a generic version of the allergy drug, the more expensive brand-name EpiPen still accounts for over a quarter of the market. One reason is that a middleman can profit from the sale of such pricier medicines. WSJ.com: What’s News US
Enlarge / BROOKLYN, NY – Monday, June 26, 2017: Martin Shkreli arrives at Brooklyn Federal Court on the first day of his securities fraud trial. (credit: Getty | Kevin Hagen) Martin Shkreli appeared in a New York federal court Monday for the start of his securities fraud trial—and was quickly declared guilty of price gouging […]